SA
AZN icon

Scarborough Advisors’s AstraZeneca AZN Stock Holding History

Scarborough Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60
Closed -$11.8K – 195
2026
Q1 		$11.8K Hold
60
– – ﹤0.01% 417
2025
Q4 		$11K Hold
60
– – ﹤0.01% 258
2025
Q3 		$9.21K Hold
60
– – ﹤0.01% 261
2025
Q2 		$8.39K Buy
+60
New +$8.41K ﹤0.01% 253
2024
Q3 		– Sell
-115
Closed -$17.9K – 144
2024
Q2 		$17.9K Hold
115
– – 0.01% 168
2024
Q1 		$15.6K Hold
115
– – 0.01% 179
2023
Q4 		$15.5K Buy
+115
New +$14.9K ﹤0.01% 313

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Scarborough Advisors's AZN Position: Q2 2026 in Review

Scarborough Advisors sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 60 shares — an estimated $11.8K sold.

Scarborough Advisors first reported a position in AZN in Q4 2023 and held it in 7 quarters. The position peaked at $17.9K in Q2 2024. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Scarborough Advisors reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 60 AstraZeneca shares in Q2 2026, an estimated $11.8K.
  • Scarborough Advisors first reported a position in AstraZeneca in Q4 2023 and held it in 7 quarters.
  • Scarborough Advisors's AstraZeneca position peaked at $17.9K in Q2 2024.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.